Fate Therapeutics Inc (NASDAQ:FATE) shares, rose in value on Thursday, July 10, with the stock price up by 0.87% to the previous day’s close as strong demand from buyers drove the stock to $1.16.
Actively observing the price movement in the last trading, the stock closed the session at $1.15, falling within a range of $1.135 and $1.1793. The value of beta (5-year monthly) was 2.231. Referring to stock’s 52-week performance, its high was $5.92, and the low was $0.66. On the whole, FATE has fluctuated by -23.68% over the past month.
With the market capitalization of Fate Therapeutics Inc currently standing at about $132.98 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FATE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of FATE currently trading nearly -1.84% and -3.61% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.41, while the 7-day volatility ratio is showing 4.75% which for the 30-day chart, stands at 8.96%. Furthermore, Fate Therapeutics Inc (FATE)’s beta value is 2.24.
A comparison of Fate Therapeutics Inc (FATE) with its peers suggests the former has fared considerably weaker in the market. FATE showed an intraday change of 0.87% in last session, and over the past year, it shrunk by -29.70%%.
Data on historical trading for Fate Therapeutics Inc (NASDAQ:FATE) indicates that the trading volumes over the past 10 days have averaged 1.84 and over the past 3 months, they’ve averaged 1.98 million. According to company’s latest data on outstanding shares, there are 114.60 million shares outstanding.
Nearly 6.58% of Fate Therapeutics Inc’s shares belong to company insiders and institutional investors own 84.22% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.51 million shares as on 2025-06-13, resulting in a short ratio of 4.62. According to the data, the short interest in Fate Therapeutics Inc (FATE) stood at 948.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 12.87 million. The stock has fallen by -62.82% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FATE stock heading into the next quarter.
